Diarmuid Moran to Drug Resistance, Neoplasm
This is a "connection" page, showing publications Diarmuid Moran has written about Drug Resistance, Neoplasm.
Connection Strength
0.043
-
A Phase I, Dose Escalation Study of Oral ASP8273 in Patients with Non-small Cell Lung Cancers with Epidermal Growth Factor Receptor Mutations. Clin Cancer Res. 2017 Dec 15; 23(24):7467-7473.
Score: 0.028
-
Transient nutlin-3a treatment promotes endoreduplication and the generation of therapy-resistant tetraploid cells. Cancer Res. 2008 Oct 15; 68(20):8260-8.
Score: 0.015